Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial
Clinical Infectious Diseases · 16.09.2025 · 81 (2) · 322-332
DOI: 10.1093/cid/ciaf077 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Clinical Infectious Diseases, online erschienen am 13.03.2025. Verfasst von Jürgen K Rockstroh und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine I, University Hospital Bonn, Bonn, Germany. Hauptthemen laut MEDLINE: HIV Infections, Pyridones, Anti-HIV Agents, Triazoles. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Merck & Co, Inc.
Abstract (Originalsprache)
Background
Doravirine/islatravir is an investigational regimen that is being studied for human immunodeficiency virus type 1 (HIV-1) treatment.
Methods
In this phase 3, double-blind, double-dummy trial (ClinicalTrials.gov NCT04233879), previously untreated adults with HIV-1 were randomized (1:1) and stratified by HIV-1 RNA (≤/>100 000 copies/mL) and CD4 count (</≥200 cells/µL) to doravirine/islatravir (100/0.75 mg) or bictegravir/emtricitabine/tenofovir alafenamide (50/200/25 mg) orally once-daily (primary endpoint: percentage of participants with HIV-1 RNA <50 copies/mL at week 48; US Food and Drug Administration snapshot, 10% noninferiority margin).
Results
Overall, 597 participants were treated; enrollment stopped early due to decreases in CD4 and lymphocyte counts observed in other islatravir studies. Doravirine/islatravir was noninferior to bictegravir/emtricitabine/tenofovir alafenamide: 265 of 298 (88.9%) versus 264 of 299 (88.3%) had HIV-1 RNA <50 copies/mL (difference, 0.5%; 95% confidence interval [CI]: −4.7, 5.6). Mean change from baseline in CD4 count was +182 and +234 cells/µL (difference, −50; 95% CI: −79, −21) with doravirine/islatravir versus bictegravir/emtricitabine/tenofovir alafenamide. Mean change in lymphocyte count was 0.01 and 0.21 × 109/L (difference, −0.20; 95% CI: −0.30, −0.10). Adverse events (AEs) occurred in 90.6% and 87.3% of participants, with coronavirus disease 2019 being most common (14.1%, 16.4%). Treatment-related AEs were similar (28.9%, 25.8%). AEs that led to discontinuations were higher with doravirine/islatravir (8.7%, 3.7%) due to protocol-specified criteria that required discontinuation for decreased CD4 and lymphocyte counts.
Conclusions
Doravirine/islatravir (100/0.75 mg) once-daily was noninferior to bictegravir/emtricitabine/tenofovir alafenamide through week 48 for initial HIV-1 treatment. Due to decreases in CD4 and lymphocyte counts, development of this dose of doravirine/islatravir was stopped. Clinical Trials Registration NCT04233879.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine I, University Hospital Bonn, Bonn, Germany.
- Department of Infectious Diseases, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
- IrsiCaixa AIDS Research Institute, Badalona, Spain.
- Center for Global Health and Diseases, Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
- Fundación Huésped, Buenos Aires, Argentina.
- University of Paris Cité, INSERM UMR1342 Biology and Pathogenesis of Viral Infections, IRSL, Paris, France.
ORCID-Profile: Jürgen K Rockstroh, Roger Paredes, Pedro Cahn, Simiso M Sokhela, Federico Hinestrosa, Sheetal Kassim, Jade Ghosn, Hiroyuki Gatanaga, Ying Zhang, Stephanie O Klopfer, Karen Eves
Förderung
- Merck & Co, Inc
Zitieren
APA
Rockstroh, J. K., Paredes, R., Cahn, P., Molina, J. M., Sokhela, S. M., Hinestrosa, F., Kassim, S., Cunningham, D., Ghosn, J., Bogner, J. R., Gatanaga, H., Asante-Appiah, E., Zhang, Y., Nwoke, U., Klopfer, S. O., Eves, K., Squires, K., Correll, T., Fox, M. C., & Pisculli, M. L. (2025). Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial. Clinical Infectious Diseases, 81(2), 322-332. https://doi.org/10.1093/cid/ciaf077
Vancouver
Rockstroh JK, Paredes R, Cahn P, Molina JM, Sokhela SM, Hinestrosa F, et al. Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial. Clinical Infectious Diseases. 2025;81(2):322-332. doi:10.1093/cid/ciaf077
BibTeX
@article{Rockstroh2025,
author = {Rockstroh, Jürgen K and Paredes, Roger and Cahn, Pedro and Molina, Jean-Michel and Sokhela, Simiso M and Hinestrosa, Federico and Kassim, Sheetal and Cunningham, Douglas and Ghosn, Jade and Bogner, Johannes R and Gatanaga, Hiroyuki and Asante-Appiah, Ernest and Zhang, Ying and Nwoke, Uchechukwu and Klopfer, Stephanie O and Eves, Karen and Squires, Kathleen and Correll, Todd and Fox, Michelle C and Pisculli, Mary L},
title = {Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial},
journal = {Clinical Infectious Diseases},
year = {2025},
volume = {81},
number = {2},
pages = {322--332},
doi = {10.1093/cid/ciaf077}
}
EUVIMED